QTTB
$6.13
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is...
Recent News
Best Momentum Stocks to Buy for March 13th
QTTB, DXPE and TTEC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 13th, 2026.
Wall Street Analysts See a 103.55% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
The mean of analysts' price targets for Q32 Bio (QTTB) points to a 103.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Q32 Bio: Q4 Earnings Snapshot
WALTHAM, Mass. AP) — Q32 Bio Inc. QTTB) on Tuesday reported net income of $57.7 million in its fourth quarter.
Q32 Bio Spotlights Bempikibart AA Data Ahead, Sharpens Focus After Asset Sale at Oppenheimer Confab
Executives from Q32 Bio (NASDAQ:QTTB) detailed progress on the company’s lead program, bempikibart, during a discussion at Oppenheimer’s 36th Annual Life Science Conference, emphasizing upcoming data in alopecia areata (AA) and a sharpened corporate focus following the divestiture of a non-core asse
This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here?
Q32 Bio stock soared after the biotech firm divested its ADX-097 to Akebia Therapeutics for $12 million. Here’s how you should play QTTB shares heading into 2026.